Ramelteon Tablet
Brand names: Rozerem
Category: Psychiatry
FDA status: To Be Discontinued · Last FDA update: Mar 19, 2026 · First posted: Mar 19, 2026 · 1 manufacturers, 2 listed presentations
As of Mar 19, 2026, the FDA lists Ramelteon Tablet as being discontinued. Of 2 manufacturer presentations, 2 Not specified.
| Presentation & package NDC | Manufacturer | Availability | FDA note |
|---|---|---|---|
| Rozerem, Tablet, 8 mg (NDC 64764-805-10) NDC 64764-805-10 |
Takeda Pharmaceuticals USA Inc. | Not specified | Product is expected to be available through February 2027. |
| Rozerem, Tablet, 8 mg (NDC 64764-805-30) NDC 64764-805-30 |
Takeda Pharmaceuticals USA Inc. | Not specified | Product is expected to be available through June 2027. |
Related medications in shortage
Other Psychiatry medications currently on the FDA shortage list — useful context if you and your prescriber are weighing alternatives. Always confirm with your pharmacist.
Change log
Tracking began Oct 1, 2026. We check the FDA every 6 hours; any real change - a manufacturer moving from Limited to Available, a new recovery date, a new listing - shows up here with its date.
Cite this: “FDA drug-shortage status for Ramelteon Tablet (FDA data as of Mar 19, 2026). Shortage Watch, openFDA.”
Get an email when this record changes
One email, only when the FDA changes something for Ramelteon Tablet. You confirm by clicking a link first (double opt-in). No newsletter, no other mail.
Feeds instead of email: RSS or JSON. Unsubscribe anytime; see Privacy.
Embed a live status badge: /badge/ramelteon-tablet.svg
FDA data last synced Oct 1, 2026 (FDA record dated Sep 30, 2026).